Your browser doesn't support javascript.
loading
1,2,3,4,6-Penta-O-galloyl-ß-D-glucose Inhibits CD44v3, a cancer stem cell marker, by regulating its transcription factor, in human pancreatic cancer cell line.
Kim, Eun-Young; Lee, Seong-Uk; Kim, Yoon Hee.
Afiliação
  • Kim EY; Department of Food and Nutrition, Daegu University, Gyeongsan-si, Republic of Korea.
  • Lee SU; Department of Food and Nutrition, Daegu University, Gyeongsan-si, Republic of Korea.
  • Kim YH; Department of Food and Nutrition, Daegu University, Gyeongsan-si, Republic of Korea.
Anim Cells Syst (Seoul) ; 26(6): 328-337, 2022.
Article em En | MEDLINE | ID: mdl-36605595
ABSTRACT
Inhibition of cluster of differentiation 44 (CD44), a pancreatic cancer stem cell (CSC) marker, is a potential treatment for pancreatic ductal adenocarcinoma (PDAC). In this study, we evaluated the effect of 1,2,3,4,6-penta-O-galloyl-ß-D-glucose (PGG), a gallotannin contained in various medicinal plants, on CD44 standard (CD44s) and CD44 variant 3 (CD44v3) in Mia-PaCa-2, human pancreatic cancer cells and explored the underlying mechanisms. PGG showed cytotoxic effects and inhibited the proliferation of Mia-PaCa-2 cells. It also inhibited clonogenic activity, adhesion to fibronectin, and cell migration, which are characteristics of CSCs. PGG inhibited the expression of CD44s and CD44v3 by inducing the phosphorylation of p53 and suppressing NF-κB and Foxo3. Inhibition of Foxo3 induces CD44v3 ubiquitination. Indeed, PGG increased proteasome activity and promoted CD44v3 ubiquitination. PGG downregulated the CSC regulatory factors Nanog, Oct-4, and Sox-2, which act downstream of CD44v3 signaling. These data indicate that PGG may have therapeutic effects in pancreatic cancer mediated by inhibition of CSC markers.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Anim Cells Syst (Seoul) Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Anim Cells Syst (Seoul) Ano de publicação: 2022 Tipo de documento: Article